NDA Submission Completed for Zipalertinib + Chemo in 1L EGFR Exon 20 Ins Mutation NSCLC November 18, 2026
CRL Received from FDA for BLA Application Based on HARMONi Study of ivonescimab + platinum-containing chemo for EGFR TKI-treated NSCLC patients November 18, 2026
Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for ccRCC Following Treatment With an Anti-PD-1/PD-L1 Therapy November 18, 2026
FDA Accepts sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer November 18, 2026
Not Approvable Letter received from the FDA in response to PMA application for Optune Mya® in NSCLC patients with brain mets following stereotactic radiation November 18, 2026
FDA RMAT and Fast Track Designations for Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma November 18, 2026
Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Ph 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Announced November 11, 2026
Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan November 11, 2026
Lirafugratinib (Lyrfigtu) Added to NCCN Guidelines as 2L Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement November 11, 2026
FDA PDUFA Date for Resubmitted NDA for Rivoceranib + Camrelizumab combo in 1L Unresectable or Metastatic HCC Announced November 11, 2026
FDA approves the investigator-sponsored clinical trial (IST) of HMBD-002 in combination with venetoclax and azacitidine in AML and MDS November 4, 2026
FDA provides Feedback in Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors October 28, 2026
CHMP recommends approval of TALVEY® (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma October 27, 2026
New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) accepted for review by the China NMPA October 27, 2026
FDA granted Fast Track designation to QTX3034 + cetuximab for KRASG12D-mutant CRC, with or without FOLFOX chemotherapy October 20, 2026